SEC Form SC 13D/A filed by Oblong Inc. (Amendment)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Oblong, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

674434 105

(CUSIP Number)

Jason M. Lynch

General Counsel

Foundry Group

645 Walnut Street

Boulder, CO 80302 

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 30, 2023

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Explanatory Note: This Amendment No. 1 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on February 22, 2021 (the “Original Schedule 13D”) filed on behalf of Foundry Group Select Fund, L.P. (“Foundry Select”), Foundry Select Fund GP, LLC (“Foundry Select GP”), Foundry Venture Capital 2007, L.P. (“Foundry 2007”), Foundry Venture 2007, LLC (“Foundry Venture”), Bradley Feld ("Feld"), Seth Levine ("Levine") and Ryan McIntyre ("McIntyre" and together with Foundry Select, Foundry Select GP, Foundry 2007, Foundry Venture, Feld and Levine, collectively, the “Reporting Persons”), relates to the Common Stock, par value $0.0001 per share (“Common Stock”) of Oblong, Inc., a Delaware corporation (the “Issuer”). Information reported in the Original Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Original Schedule 13D. All references in the Original Schedule 13D and this Amendment shall be deemed to refer to the Original Schedule 13D as amended and supplemented by this Amendment.

Item 2(b) of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 4:

On June 30, 2023, the Issuer entered into an exchange agreement (the “Exchange Agreement”) with Foundry Select and Foundry 2007 (the “Exchanging Stockholders”), pursuant to which, effective July 3, 2023, the Issuer exchanged an aggregate of 406,776 shares of the Issuer’s Common Stock, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 406,776 shares of Common Stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting Common Stock), with an exercise price of $0.0001 per share, as described more fully below.

Immediately after the closing of the transactions contemplated by the Exchange Agreement, the Exchanging Stockholders owned an aggregate of 115,859 shares of Common Stock representing approximately 4.99% of the total number of issued and outstanding Common Stock as of such date.

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

(a), (b)       The responses of the Reporting Persons with respect to Rows 7 through 13 of their respective cover pages to this Schedule 13D are incorporated herein by reference.

The Reporting Persons beneficially own, in the aggregate, 115,859 shares of Common Stock, representing approximately 4.99% of the outstanding shares of Common Stock, based upon 2,728,600 shares of Common Stock outstanding as of June 30, 2023, as reported by the Issuer directly to the Reporting Persons on June 30, 2023, minus an aggregate of 406,776 shares of Common Stock exchanged by the Reporting Persons for Exchange Warrants as described above.

Each of the Reporting Persons expressly disclaims beneficial ownership of all of the shares of Common Stock included in this Amendment, other than the shares of Common Stock held of record by such Reporting Person, and expressly disclaim status as a “group” for purposes of this Amendment. The filing of this Amendment shall not be construed as an admission that any such person is, for the purposes of sections 13(d) or 13(g) of the Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this Amendment.

Item 6 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 6:

Exchange Agreement

The description of the Exchange Agreement in Item 4 is incorporated by reference herein.

Pre-Funded Warrants to Purchase Common Stock

The Exchange Warrants are exercisable at any time, except that the Exchange Warrants are not exercisable by the Exchanging Stockholders if, upon giving effect or immediately prior thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the total number of issued and outstanding Common Stock, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Issuer. The holders of the Exchange Warrants will not have the right to vote on any matter submitted to the Issuer’s holders of Common Stock, except to the extent required by Delaware law.

The foregoing descriptions are qualified in their entirety by the full text of the Exchange Agreement and form of Exchange Warrant, which are filed herewith as Exhibits C and D and incorporated herein by reference.

Item 7 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end of Item 7:

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)